nejm semaglutide cardiovascular and Outcomes in Obesity without Diabetes | Cardiovascular outcomes of semaglutide and

These rates are similar to the rates last year for both small firms and large firms [Figure 3.1]

For severe obesity specifically, these are not comparable outcomes

Adverse events in relation to GLP-1R agonists for the treatment of obesity are mainly gastrointestinal side effects, including nausea, diarrhoea, vomiting and constipation, which is consistent with observations in type 2 diabetes, and rates of discontinuation due to adverse events are generally higher with GLP-1R agonists treatment compared with placebo [26, 30,31,32,33,34,35,36,37,38,39]

Experts don't recommend melatonin for insomnia, the sleep issue most commonly faced by pregnant women

Parte de estudios cientficos que tienen su propio proceso de validacin por parte de revistas especializadas en salud, fuentes confiables que son lderes de opinin de Sociedades Cientficas, Colegios Profesionales, Universidades y Hospitales de prestigio, entre otros